Cargando…

TMS-EEG perturbation biomarkers for Alzheimer’s disease patients classification

The combination of TMS and EEG has the potential to capture relevant features of Alzheimer’s disease (AD) pathophysiology. We used a machine learning framework to explore time-domain features characterizing AD patients compared to age-matched healthy controls (HC). More than 150 time-domain features...

Descripción completa

Detalles Bibliográficos
Autores principales: Tăuƫan, Alexandra-Maria, Casula, Elias P., Pellicciari, Maria Concetta, Borghi, Ilaria, Maiella, Michele, Bonni, Sonia, Minei, Marilena, Assogna, Martina, Palmisano, Annalisa, Smeralda, Carmelo, Romanella, Sara M., Ionescu, Bogdan, Koch, Giacomo, Santarnecchi, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175269/
https://www.ncbi.nlm.nih.gov/pubmed/37169900
http://dx.doi.org/10.1038/s41598-022-22978-4
Descripción
Sumario:The combination of TMS and EEG has the potential to capture relevant features of Alzheimer’s disease (AD) pathophysiology. We used a machine learning framework to explore time-domain features characterizing AD patients compared to age-matched healthy controls (HC). More than 150 time-domain features including some related to local and distributed evoked activity were extracted from TMS-EEG data and fed into a Random Forest (RF) classifier using a leave-one-subject out validation approach. The best classification accuracy, sensitivity, specificity and F1 score were of 92.95%, 96.15%, 87.94% and 92.03% respectively when using a balanced dataset of features computed globally across the brain. The feature importance and statistical analysis revealed that the maximum amplitude of the post-TMS signal, its Hjorth complexity and the amplitude of the TEP calculated in the window 45–80 ms after the TMS-pulse were the most relevant features differentiating AD patients from HC. TMS-EEG metrics can be used as a non-invasive tool to further understand the AD pathophysiology and possibly contribute to patients’ classification as well as longitudinal disease tracking.